Role of allogeneic stem cell transplantation in mantle cell lymphoma

Jonathon B. Cohen, Linda J. Burns, Veronika Bachanova

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations


Despite a wide spectrum of treatment options, mantle cell lymphoma (MCL) remains a challenging hematologic malignancy to manage. Advances in front-line therapy, including the monoclonal antibody rituximab and increasing use of cytarabine, have improved remission rates. Autologous hematopoietic cell transplantation (HCT) can effectively consolidate remission of MCL, leading to encouraging survival beyond 5 yr. However, nearly all patients with MCL will relapse and require salvage therapy. Novel agents such as ibrutinib, bortezomib, and lenalidomide have dramatically expanded the options for treating relapsed MCL. In this review, we summarize the clinical evidence supporting the use of allogeneic donor HCT in MCL and make recommendations on indications for its use. Data suggest that allogeneic donor HCT is the only curative therapy for patients with poor prognosis or aggressive MCL. Patient selection, timing, and optimal use remain a matter of scientific debate and given the rapidly changing therapeutic landscape of MCL, the outcomes of allogeneic HCT should be interpreted in the context of novel therapeutics.

Original languageEnglish (US)
Pages (from-to)290-297
Number of pages8
JournalEuropean Journal of Haematology
Issue number4
StatePublished - Apr 1 2015

Bibliographical note

Publisher Copyright:
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.


  • Allogeneic donor
  • Hematopoetic cell transplantation
  • Mantle cell lymphoma
  • Review


Dive into the research topics of 'Role of allogeneic stem cell transplantation in mantle cell lymphoma'. Together they form a unique fingerprint.

Cite this